LABORATORY RESEARCH Autocrine Motility Factor Promotes HER2 Cleavage and Signaling in Breast Cancer Cells Researchers showed that autocrine motility factor binds to HER2 and induces cleavage to the ectodomain-deleted and constitutively active form p95HER2. [Cancer Res] Abstract Contrasting Hypoxic Effects on Breast Cancer Stem Cell Hierarchy Is Dependent on ERα Status Scientists studied the effects of hypoxia on cancer stem cel activity, using in vitro mammosphere and holoclone assays as well as in vivo limiting dilution experiments, in 13 patient-derived samples and four cell lines. [Cancer Res] Abstract Fibroblast Growth Factor Receptor Signaling Is Essential for Normal Mammary Gland Development and Stem Cell Function Using a conditional deletion strategy, the authors investigated the consequences of fibroblast growth factor receptor-1 (FGFR1) deletion alone and then the simultaneous deletion of both FGFR1 and FGFR2 in the mammary epithelium. [Stem Cells] Abstract ROCK1 Inhibition Promotes the Self-Renewal of a Novel Mouse Mammary Cancer Stem Cell Researchers identified epithelial tumor-initiating cells that express lineage markers of both basal and luminal mammary cell lineages and retain the potential, from even single cells, to generate heterogeneous tumors similar to the tumor of origin. [Stem Cells] Abstract Depletion of Tristetraprolin in Breast Cancer Cells Increases Interleukin-16 Expression and Promotes Tumor Infiltration with Monocytes/Macrophages As immune cell infiltration into tumors is a critical determinant for tumor progression, the authors aimed to determine the influence of tumor cell tristetraprolin on the interaction between tumor and immune cells, specifically monocytes/macrophages. [Carcinogenesis] Abstract Estrogen Switches Pure Mucinous Breast Cancer to Invasive Lobular Carcinoma with Mucinous Features Because of the relative rarity of pure mucinous breast cancer (MBC), little is known about its cell and tumor biology and relationship to invasive disease of other subtypes. Investigators have developed a human breast cancer cell line called BCK4, in which they can control the behavior of MBC. [Breast Cancer Res Treat] Abstract Differential Expression of Immune-Related Markers in Breast Cancer by Molecular Phenotypes Scientists aimed to investigate the relationship between expression of immune-related molecules such as STAT1, CD20, IL-8, IFN-γ, tumor genetic phenotype, and the clinical course of invasive breast cancer. [Breast Cancer Res Treat] Abstract CLINICAL RESEARCH Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide in Node-Positive Breast Cancer: Ten-Year Follow-Up of the Phase III Randomized BCIRG 001 Trial Researchers compared standard adjuvant anthracycline chemotherapy with anthracycline-taxane combination chemotherapy in women with operable node-positive breast cancer. Here they report the final, ten-year follow-up analysis of disease-free survival, overall survival, and long-term safety. [Lancet Oncol] Abstract A Phase II Study of UCN-01 in Combination with Irinotecan in Patients with Metastatic Triple Negative Breast Cancer The high frequency of TP53 mutations in triple negative breast cancer (TNBC) make checkpoint kinase 1 (Chk1) an attractive therapeutic target. UCN-01, a non-selective Chk1 inhibitor, combined with irinotecan demonstrated activity in advanced TNBC in a previous Phase I study. Researchers aimed to further evaluate this treatment in women with TNBC. [Breast Cancer Res Treat] Full Article |